论文部分内容阅读
β-肾上腺素能受体阻滞剂(以下简称β-阻滞剂)用于冠心病防治已有20年历史。70年代初的临床随机研究证实,心肌梗塞患者应用该药有减少死亡率之倾向。1975年以来,国际多中心试验、挪威多中心试验、瑞典的美多心安试验及涉及全美31个医学中心的β-阻滞剂心脏发作试验证实,急性心肌梗塞患者中,β-阻滞剂可减少死亡率和非致命性再梗塞的发生。而改善预后、防止梗塞的再发生是缺血性心脏病患者二线预防和康复治疗的核心问题,因而为临床工作者所关注。一、β-阻滞剂对缺血性心脏病的作用随着临床的广泛应用,β-阻滞剂已合成10余种。这些药物的共同作用机制是附着于β-受体上成为儿茶
β-adrenergic receptor blockers (hereinafter referred to as β-blockers) for the prevention and treatment of coronary heart disease for 20 years. Clinical randomized studies in the early 1970s confirmed that the use of this drug in patients with myocardial infarction tends to reduce mortality. Since 1975, the international multicentre trial, the Norwegian multicentre trial, the methadone trial in Sweden and the β-blocker heart attack trial involving 31 medical centers across the United States have shown that β-blockers in patients with acute myocardial infarction Reduce mortality and non-fatal recanalization. Improving prognosis and preventing the recurrence of infarction are the core issues of second-line prevention and rehabilitation treatment in patients with ischemic heart disease, which is of great concern to clinicians. First, the role of β-blockers on ischemic heart disease With the widespread use of clinical, β-blockers have been synthesized more than 10 species. The common mechanism of action of these drugs is to attach to the beta-receptor to become catechu